Company news
Disc Medicine, Inc. (NASDAQ:IRON) news
Disc Medicine, Inc. news releases on 6ix. Latest, Nov 4, 2024: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin…
Press releases — page 2
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
November 3, 2024
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
October 31, 2024
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
October 24, 2024
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
October 22, 2024
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
October 10, 2024
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
September 18, 2024
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
June 13, 2024
Disc Medicine Announces Underwritten Offering of Common Stock
June 13, 2024
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
May 13, 2024
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
May 12, 2024
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
March 31, 2024
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 20, 2024
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
March 5, 2024
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
February 25, 2024
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
February 19, 2024
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
February 8, 2024
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
February 6, 2024
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
December 19, 2023
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
December 10, 2023
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
December 10, 2023
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
November 13, 2023
Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
November 8, 2023
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates
November 1, 2023
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
October 22, 2023
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
October 2, 2023
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
September 19, 2023
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
July 26, 2023
Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 21, 2023
Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2023
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
June 8, 2023
Disc Medicine to Participate in the Jefferies Healthcare Conference
May 30, 2023
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
May 14, 2023
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
May 10, 2023
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
April 20, 2023
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
April 12, 2023
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
March 20, 2023
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
February 15, 2023
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
February 13, 2023
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
February 7, 2023
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
January 19, 2023
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria
December 26, 2022
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)
October 30, 2022
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
August 9, 2022
Gemini Therapeutics Reports 2021 Financial Results
March 9, 2022